BridgeBio Pharma BBIO) stock received a Perform rating from Oppenheimer on market challenges to its late-stage assets acoramidis and infigratinib. Read more here.

Analyst Kostas Biliouris of BMO Capital maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report), retaining the price target ...

Its product portfolio includes several high-impact treatments such as Voxzogo and Roctavian, addressing conditions like ...

The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 ...

Much of Josie’s confidence in navigating adolescence as a little person is thanks to her involvement with Little People of ...

Josie Tang Tsz-kwan was born with achondroplasia, the most common form of short-limbed dwarfism. People with this condition ...

A Dalmatian called Dino has become a viral sensation on social media for his small stuature. The dog has dwarfism condition, ...